Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonafarnib - Eiger Biopharmaceuticals

Drug Profile

Lonafarnib - Eiger Biopharmaceuticals

Alternative Names: EBP 994; MK-6336; Sarasar; SCH 066336; SCH 66336; Zokinvy

Latest Information Update: 05 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Eiger BioPharmaceuticals, Inc.; Merck & Co; Schering-Plough
  • Class Amides; Antineoplastics; Antivirals; Benzene derivatives; Halogenated hydrocarbons; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progeria; Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Progeria
  • Phase III Hepatitis D
  • Discontinued Breast cancer; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 04 Apr 2023 Eiger Biopharmaceuticals receives notice of orphan drug designation from the Japanese Ministry of Health, Labour and Welfare for lonafarnib in Progeria before April 2023
  • 24 Mar 2023 Eiger Biopharmaceuticals completes the pivotal phase III D-LIVR trial for Hepatitis D (Combination-therapy) in the US, Belgium, Bulgaria, Canada, France, Greece, Italy, Mangolia, Moldova, New Zealand, Romania, Spain, Sweden, Taiwan, Turkey, United Kingdom, Ukraine, Israel, Pakistan, Germany and Switzerland and Russia (PO, Capsule) (NCT03719313) (EudraCT2018-003167-54)
  • 16 Mar 2023 Eiger BioPharmaceuticals plans a pre-NDA meeting by end of Q2 of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top